TABLE 35Results of the base-case analysis

StrategyQALYCost (£)Incremental QALYIncremental cost (£)ICERPCE
20K30K
N5.17142,168NA0.4720.309
A6.58068,6381.40926,470Ex dom0.0460.032
E7.00174,8410.4226203178530.4360.475
I7.30888,4420.30713,601443260.0460.184

A, adalimumab; E, etanercept; Ex dom, extended dominated; I, infliximab; N, palliative care; NA, not available; PCE 20K/30K – probability that the treatment is cost-effective at a threshold of £20,000/30,000 per QALY.

From: 4, Assessment of cost-effectiveness evidence

Cover of Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation
Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.10.
Rodgers M, Epstein D, Bojke L, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.